<?xml version='1.0' encoding='utf-8'?>
<document id="25850339"><sentence text="Relative contributions of the major human CYP450 to the metabolism of icotinib and its implication in prediction of drug-drug interaction between icotinib and CYP3A4 inhibitors/inducers using physiologically based pharmacokinetic modeling."><entity charOffset="70-78" id="DDI-PubMed.25850339.s1.e0" text="icotinib" /></sentence><sentence text="Icotinib is an anticancer drug, but relative contributions of CYP450 have not been identified"><entity charOffset="0-8" id="DDI-PubMed.25850339.s2.e0" text="Icotinib" /></sentence><sentence text=" This study was carried out to identify the contribution percentage of CYP450 to icotinib and use the results to develop a physiologically based pharmacokinetic (PBPK) model, which can help to predict drug-drug interaction (DDI)" /><sentence text="" /><sentence text="Human liver microsome (HLM) and supersome using relative activity factor (RAF) were employed to determine the relative contributions of the major human P450 to the net hepatic metabolism of icotinib"><entity charOffset="190-198" id="DDI-PubMed.25850339.s5.e0" text="icotinib" /></sentence><sentence text=" These values were introduced to develop a PBPK model using SimCYP" /><sentence text=" The model was validated by the observed data in a Phase I clinical trial in Chinese healthy subjects" /><sentence text=" Finally, the model was used to simulate the DDI with ketoconazole or rifampin"><entity charOffset="54-66" id="DDI-PubMed.25850339.s8.e0" text="ketoconazole" /><entity charOffset="70-78" id="DDI-PubMed.25850339.s8.e1" text="rifampin" /><pair ddi="false" e1="DDI-PubMed.25850339.s8.e0" e2="DDI-PubMed.25850339.s8.e0" /><pair ddi="false" e1="DDI-PubMed.25850339.s8.e0" e2="DDI-PubMed.25850339.s8.e1" /></sentence><sentence text="" /><sentence text="Final contribution of CYP450 isoforms determined by HLM showed that CYP3A4 provided major contributions to the metabolism of icotinib"><entity charOffset="125-133" id="DDI-PubMed.25850339.s10.e0" text="icotinib" /></sentence><sentence text=" The percentage contributions of the P450 to the net hepatic metabolism of icotinib were determined by HLM inhibition assay and RAF" /><sentence text=" The AUC ratio under concomitant use of ketoconazole and rifampin was 3"><entity charOffset="40-52" id="DDI-PubMed.25850339.s12.e0" text="ketoconazole" /><entity charOffset="57-65" id="DDI-PubMed.25850339.s12.e1" text="rifampin" /><pair ddi="false" e1="DDI-PubMed.25850339.s12.e0" e2="DDI-PubMed.25850339.s12.e0" /><pair ddi="false" e1="DDI-PubMed.25850339.s12.e0" e2="DDI-PubMed.25850339.s12.e1" /></sentence><sentence text="22 and 0" /><sentence text="55, respectively" /><sentence text="" /><sentence text="Percentage of contribution of CYP450 to icotinib metabolism was calculated by RAF"><entity charOffset="40-48" id="DDI-PubMed.25850339.s16.e0" text="icotinib" /></sentence><sentence text=" The model has been proven to fit the observed data and is used in predicting icotinib-ketoconazole/rifampin interaction"><entity charOffset="100-108" id="DDI-PubMed.25850339.s17.e0" text="rifampin" /></sentence><sentence text="" /></document>